Comparison · NCT02793622-sae
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy vs Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy vs Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy: serious adverse events. Trial comparisons, record NCT02793622-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02793622-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0293 | 0.0165 | 0.0518 | wilson | |
| Risk in group 2 | 0.0509 | 0.0328 | 0.0782 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0216 | -0.0517 | 0.0072 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.576 | 0.278 | 1.19 | log | |
| Odds ratio, group 1 over group 2 | 0.563 | 0.264 | 1.2 | log | |
Number needed to treat, for one fewer participant with a serious adverse event on Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy than on Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 46.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | Women will be given SP (3 full strength tabs, 500 mg/25 mg) every four weeks times during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 11 | 375 | EG000 |
| Group 2 | Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 19 | 373 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse event data were collected following the initiation of study drugs through to 6 weeks postpartum.
Source ClinicalTrials.gov
Trial
- Title
- Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
- NCT number
- NCT02793622
- Phases
- PHASE3
- Conditions
- Malaria
- Interventions
- Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy, Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy
- Lead sponsor
- University of California, San Francisco
- Results first posted
- 2021-04-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02793622?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02793622-sae